OBJECTIVES: To evaluate the cost and healthcare resource utilization (HCRU) burden of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) in the United States (US), overall and based on treatment patterns.

METHODS: A retrospective cohort study was conducted using a US claims dataset (Komodo Health closed claims, Jan 2016 – Dec 2020). Patients with CIDP were selected based on presence of: (1) ≥2 claims with CIDP diagnosis, ≥30-≤365 apart (first considered as index date), (2) ≥1 nerve conduction test present either after the index date and before another CIDP diagnosis, or ≤90 days before the index date, (3) continuous enrollment ±1 year pre- and post-index date. All-cause medical costs and HCRU were evaluated for year 1 post-index on a per-patient per-year basis. Among patients receiving immunoglobulin (IG) during year 1, those with ≥8 IG episodes (defined as clusters of IG infusions ≤5 days apart) were considered chronic IG users, while others were considered intermittent users.

RESULTS: Among 3409 patients with CIDP identified, mean HCRU and costs for treated and untreated patients in year 1 post-index were substantial (all-cause outpatient visits: 31.74; all-cause inpatient days for patients with at least 1 visit: 2.40; all-cause total cost: $105,554. Of the 1803 patients (53%) who used IG treatment at least once during year 1 post-index, 62% (n=1113/1803) were chronic IG users, and 38% (n=690/1803) were intermittent IG users. The mean annual all-cause total cost was higher in chronic IG users ($247,456) and more than 2.3-fold greater than that of overall patients with CIDP

CONCLUSIONS: Based on US claims data, the economic burden for adult patients with CIDP was driven by treatment pattern, with substantial burden observed in patients receiving chronic IG. Future studies should evaluate clinical and other unmet needs associated with common CIDP treatment patterns.